Several biotechnology companies have recently announced substantial layoffs as part of broader restructuring efforts. Agios Pharmaceuticals is cutting over 100 R&D roles, while Ultragenyx is laying off 20% of its workforce to reduce its R&D budget. Molecular Partners plans to reduce its staff by up to 44% to focus on its pipeline. Lenz Therapeutics is also making significant cuts, with 75% of its workforce being let go. These actions reflect a challenging period for the biopharmaceutical sector, with companies re-evaluating priorities and operational strategies.
https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026